Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.

Pediatric blood & cancer - 1 Jan 2021

Moskop Amy, Pommert Lauren, Thakrar Pooja, Talano Julie, Phelan Rachel

Abstract excerpt

Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow Neoplasms
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to Immunotherapy, Adoptive

Share to Kidney Neoplasms

Share to Myeloid-Lymphoid Leukemia Protein

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptors, Chimeric Antigen

Source

Identifiers

PMID: 33009894
DOI: 10.1002/pbc.28739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.PMID 33009894Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Towards targeted therapy for infant acute lymphoblastic leukaemia.Semantic proximity Read ↗

Crossing Our T’s: An Unusual Presentation of Infantile T-cell LeukemiaSemantic proximity Read ↗

Multiple Lineage Switches in KMT2A Rearranged Infant Leukemia, Responsive to Combination Therapy with CPX-351 and InotuzumabSemantic proximity Read ↗

Chimeric Antigen Receptor‐T Cell TherapySemantic proximity Read ↗

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolSemantic proximity Read ↗

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolSemantic proximity Read ↗

Azacitidine successfully maintained the second remission in an infant with KMT2A‐rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantationSemantic proximity Read ↗

KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.